Novo Nordisk

Page 2 of 8

Semaglutide medications Wegovy and Ozempic are pictured
Health

Wegovy, Ozempic shortage declared over, hitting copycats like Hims & Hers

By Bloomberg, Madison Muller, Ike Swetlitz and Naomi Kresge
February 21, 2025
A woman injects herself with medication.
Health

Ozempic, Wegovy maker calls out Hims & Hers Super Bowl ad: ‘Check before you inject’

By
February 11, 2025
Novo Nordisk President and CEO Lars Fruergaard Jorgensen testifies before the Senate Health, Education, Labor, and Pensions Committee in the Dirksen Senate Office Building on Capitol Hill on September 24, 2024 in Washington, DC. The committee heard testimony from Jorgensen about the price of popular pharmaceuticals made by Novo Nordisk that help treat diabetes and obesity, including Wegovy and Ozempic.
Leadership

As U.S. firms scrap diversity targets, the CEO behind Ozempic and Wegovy took a pay cut for missing them

By
February 5, 2025
Karsten Munk Knudsen, chief financial officer of Novo Nordisk A/S, at the company's headquarters in Bagsvaerd, Denmark, on Tuesday, Nov. 26, 2024.
Health

As growth slows, CFO says Novo Nordisk is prepping for the next generation of weight loss drugs

By
February 5, 2025
Novo Nordisk advertising logo on facade building, Danish pharmaceutical healthcare giant Novo Nordisk AS, production innovative drugs, obesity treatment Ozempic, Mainz, Germany June 15, 2024
Health

Investors are growing anxious about Novo Nordisk’s silence since disappointing CagriSema weight loss drug results

By
February 4, 2025
A person stands on a scale.
Health

Hims & Hers Super Bowl ad slams pricey pharma industry—and fumbles FDA warnings on compounded GLP-1 drugs

By
February 3, 2025
DeepSeek and Ozempic are complicating decarbonization forecasts
Environment

DeepSeek and Ozempic are complicating decarbonization forecasts

By Aaron Clark and Bloomberg
January 31, 2025
A cautionary tale that Europe can’t afford to ignore
Magazine

A cautionary tale that Europe can’t afford to ignore

By
January 31, 2025
The increase in online searches for obesity management drugs in recent years correlated to a surge in dispensed prescriptions, according to a new study from the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease.
Health

Online searches predicted the surge in prescriptions of weight-loss drugs like Wegovy and Zepbound, study says. Here’s what could happen next

By
January 29, 2025
A person, with only the midsection visible, injects Wegovy under the skin of their stomach.
Finance

Novo Nordisk stock surges 7% after Ozempic maker’s latest weight-loss drug shows promise

By
January 24, 2025
Eli Lilly & Co., the Fortune 500 pharma firm that manufactures weight-loss injection Zepbound (tirzepatide), has a comparable oral medication in the works that could be approved by the FDA as early as 2026, CEO Dave Ricks told Bloomberg TV on Jan. 13, 2025.
Health

Hate needles? Lilly’s weight-loss pill could get FDA approval next year, CEO says

By
January 22, 2025
Chairman & Chief Executive Officer of LVMH, Bernard Arnault attends the Viva Technology show at Parc des Expositions Porte de Versailles on May 23, 2024 in Paris, France.
Success

LVMH dethrones Novo Nordisk as Europe’s most valuable company as Bernard Arnault adds $12 billion to net worth in 2025

By
January 20, 2025
Danish Prime Minister Mette Frederiksen (R) and Greenlandic Prime Minister Mute Bourup Egede address a press conference in the Mirror Hall at the Prime Minister's Office, at Christiansborg in Copenhagen, on January 10, 2025.
Leadership

Novo Nordisk CEO attends crisis talks with Danish PM amid Donald Trump Greenland threats

By
January 17, 2025
Elon Musk admits he takes an Ozempic-like weight-loss drug that RFK Jr. wants to restrict
Health

Elon Musk admits he takes an Ozempic-like weight-loss drug that RFK Jr. wants to restrict

By
December 27, 2024
Novo Nordisk advertising flags and logo on facade, Danish pharmaceutical healthcare giant Novo Nordisk AS, production innovative drugs, obesity treatment Ozempic, Mainz, Germany June 15, 2024
Health

Novo Nordisk faces stock market bloodbath after weight-loss drug trial disappoints

By Ryan Hogg and AFP
December 20, 2024

Most Popular